# Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA

> **NCT03119701** · PHASE2 · TERMINATED · sponsor: **Faron Pharmaceuticals Ltd** · enrollment: 40 (actual)

## Conditions studied

- Preventive Medicine
- Multi Organ Failure

## Interventions

- **DRUG:** Interferon Beta-1A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03119701
- **Lead sponsor:** Faron Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-18
- **Primary completion:** 2019-09-23
- **Final completion:** 2019-10-03
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** IDMC recommendation. Unexpectedly high use of concomitant corticosteroid treatment.
- **Last updated:** 2021-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03119701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03119701, "Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03119701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*